Case report: Increase of NK cells and proinflammatory monocytes are associated with the clinical improvement of diffuse cutaneous leishmaniasis after immunochemotherapy with BCG/Leishmania antigens

American Journal of Tropical Medicine and Hygiene

Volumn 81, Issue 3, 2009, Pages 378-383

  Pereira, Ledice I A ^a   Dorta, Miriam L ^a   Pereira, Ana Joaquina C S ^b   Bastos, Rosidete P ^a   Oliveira, Milton A P ^a   Pinto, Sebastião A ^c   Galdino Jr , Hélio ^a   Mayrink, Wilson ^d   Barcelos, Warly ^d   Toledo, Vicente P C P ^d   Lima, Gloria Maria C A ^a   Ribeiro Dias, Fátima ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b Hospital de Doenças Tropicais Dr Anuar Auad   (Brazil)

^c Instituto Goiano de Oncologia e Hematologia   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANFORICIN B; AZIDROMIC; AZITHROMYCIN; BCG VACCINE; GAMMA INTERFERON; ISONIAZID; ISONIAZIDA; LEISHMANIA VACCINE; MEGLUMINE ANTIMONATE; RIFAMPICIN; RIFAMPICINA; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; BACTERIAL ANTIGEN; PARASITE ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; BRAZIL; CASE REPORT; CELL ACTIVATION; CELL CULTURE; CELL INFILTRATION; CELL STIMULATION; CHEMOTHERAPY; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; INNATE IMMUNITY; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEUKOCYTE COUNT; MALE; MONOCYTE; MONONUCLEAR CELL; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; RELAPSE; SKIN LEISHMANIASIS; SKIN TEST; ANIMAL; BIOASSAY; C57BL MOUSE; IMMUNOLOGY; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; LEISHMANIA MEXICANA; MOUSE;

LEISHMANIA AMAZONENSIS; LEISHMANIA BRAZILIENSIS; MYCOBACTERIUM BOVIS BCG;

ANIMALS; ANTIGENS, BACTERIAL; ANTIGENS, PROTOZOAN; ANTIPROTOZOAL AGENTS; BCG VACCINE; BIOLOGICAL ASSAY; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEISHMANIA MEXICANA; LEISHMANIASIS VACCINES; LEISHMANIASIS, DIFFUSE CUTANEOUS; MALE; MICE; MICE, INBRED C57BL; MONOCYTES; YOUNG ADULT;

EID: 69249179376     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2009.81.378     Document Type: Article

References (33)

1. Convit J, Pinardi ME, Rondon AJ, 1972. Diffuse cutaneous leishmaniasis: a disease due to an immunological defect of the host. Trans R Soc Trop Med Hyg 66: 603-610.
2. Silveira FT, Lainson R, Corbett CE, 2004. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz 99:239-251. (Pubitemid 38822274)
3. Azeredo-Coutinho RB, Conceicao-Silva F, Schubach A, Cupolillo E, Quintella LP, Madeira MF, Pacheco RS, Valete-Rosalino CM, Mendonca SC, 2007. First report of diffuse cutaneous leishmaniasis and Leishmania amazonensis infection in Rio de Janeiro State, Brazil. Trans R Soc Trop Med Hyg 101: 735-737. (Pubitemid 46706145)
4. Salaiza-Suazo N, Volkow P, Tamayo R, Moll H, Gillitzer R, Perez-Torres A, Perez-Montfort R, Dominguez JD, Velasco-Castrejon O, Crippa M, Becker I, 1999. Treatment of two patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana modifies the immunohistological profile but not the disease outcome. Trop Med Int Health 4: 801-811. (Pubitemid 30041033)
5. Becker I, Volkow P, Velasco-Castrejon O, Salaiza-Suazo N, Berzunza-Cruz M, Dominguez JS, Morales-Vargas A, Ruiz-Remigio A, Perez-Montfort R, 1999. The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis. Parasitol Res 85: 165-170. (Pubitemid 29046753)
6. Zerpa O, Ulrich M, Blanco B, Polegre M, Avila A, Matos N, Mendoza I, Pratlong F, Ravel C, Convit J, 2007. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 156: 1328-1335. (Pubitemid 47029811)
7. Convit J, 1996. Leishmaniasis: immunological and clinical aspects and vaccines in Venezuela. Clin Dermatol 14: 479-487. (Pubitemid 26327741)
8. Convit J, Ulrich M, Polegre MA, Avila A, Rodriguez N, Mazzedo MI, Blanco B, 2004. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem Inst Oswaldo Cruz 99: 57-62. (Pubitemid 38406266)
9. Suttmann H, Jacobsen M, Reiss K, Jocham D, Bohle A, Brandau S, 2004. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol 172: 1490-1495. (Pubitemid 39249755)
10. Liew FY, Li Y, Millott S, 1990. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 145: 4306-4310.
11. Nascimento FR, Ribeiro-Dias F, Russo M, 1998. Cytotoxic activity of BCG-activated macrophages against L929 tumor cells is nitric oxide-dependent. Braz J Med Biol Res 31: 1593-1596. (Pubitemid 128524845)
12. Mukbel RM, Patten C Jr, Gibson K, Ghosh M, Petersen C, Jones DE, 2007. Macrophage killing of Leishmania amazonensis amastigotes requires both nitric oxide and superoxide. Am J Trop Med Hyg 76: 669-675. (Pubitemid 351627705)
13. Aranha FC, Ribeiro U Jr, Basse P, Corbett CE, Laurenti MD, 2005. Interleukin-2-activated natural killer cells may have a direct role in the control of Leishmania (Leishmania) amazonensis promastigote and macrophage infection. Scand J Immunol 62: 334-341. (Pubitemid 41565385)
14. Esin S, Batoni G, Pardini M, Favilli F, Bottai D, Maisetta G, Florio W, Vanacore R, Wigzell H, Campa M, 2004. Functional characterization of human natural killer cells responding to Mycobacterium bovis bacille Calmette-Guerin. Immunology 112: 143-152. (Pubitemid 38609832)
15. Scharton TM, Scott P, 1993. Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 178: 567-577. (Pubitemid 23218205)
16. Sambrook J, Fritsch E, Maniatis T, 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
17. Uliana SR, Nelson K, Beverley SM, Camargo EP, Floeter-Winter LM, 1994. Discrimination amongst Leishmania by polymerase chain reaction and hybridization with small subunit ribosomal DNA derived oligonucleotides. J Eukaryot Microbiol 41: 324-330. (Pubitemid 2130931)
18. Savani ES, Nunes VL, Galati EA, Castilho TM, Araujo FS, Ilha IM, Camargo MC, D'Auria SR, Floeter-Winter LM, 2005. Occurrence of co-infection by Leishmania (Leishmania) chagasi and Trypanosoma (Trypanozoon) evansi in a dog in the state of Mato Grosso do Sul, Brazil. Mem Inst Oswaldo Cruz 100: 739-741.
19. Mendonca SC, De Luca PM, Mayrink W, Restom TG, Conceicao-Silva F, Da-Cruz AM, Bertho AL, Da Costa CA, Genaro O, Toledo VP, Coutinho SG, 1995. Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis. Am J Trop Med Hyg 53: 195-201.
20. Mayrink W, Botelho AC, Magalhaes PA, Batista SM, Lima Ade O, Genaro O, Costa CA, Melo MN, Michalick MS, Williams P, Dias M, Caiaffa WT, Nascimento E, Machado-Coelho GL, 2006. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop 39: 14-21. (Pubitemid 43305007)
21. Toledo VP, Mayrink W, Gollob KJ, Oliveira MA, Costa CA, Genaro O, Pinto JA, Afonso LC, 2001. Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment. Mem Inst Oswaldo Cruz 96: 89-98. (Pubitemid 33639461)
22. Gaddy J, Broxmeyer HE, 1997. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol 180: 132-142. (Pubitemid 27459747)
23. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA, 2001. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97: 3146-3151.
24. Ziegler-Heitbrock HW, 1996. Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. Immunol Today 17: 424-428.
25. Cabrera M, Blackwell JM, Castes M, Trujillo D, Convit J, Shaw MA, 2000. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol 22: 73-79. (Pubitemid 30098807)
26. von Meyenn F, Schaefer M, Weighardt H, Bauer S, Kirschning CJ, Wagner H, Sparwasser T, 2006. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells. Immunobiology 211: 557-565. (Pubitemid 44241634)
27. Sorensen AL, Kharazmi A, Nielsen H, 1989. Leishmania interaction with human monocytes and neutrophils: modulation of the chemotactic response. Apmis 97: 754-760. (Pubitemid 19217694)
28. Nylen S, Maasho K, Soderstrom K, Ilg T, Akuffo H, 2003. Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin Exp Immunol 131: 457-467. (Pubitemid 36324137)
29. Cooper MA, Fehniger TA, Caligiuri MA, 2001. The biology of human natural killer-cell subsets. Trends Immunol 22: 633-640.
30. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L, 2008. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 15: 226-233.
31. Bomfim G, Nascimento C, Costa J, Carvalho EM, Barral-Netto M, Barral A, 1996. Variation of cytokine patterns related to therapeutic response in diffuse cutaneous leishmaniasis. Exp Parasitol 84: 188-194. (Pubitemid 26399785)
32. Soares G, Barral A, Costa JM, Barral-Netto M, Van Weyenbergh J, 2006. CD16+ monocytes in human cutaneous leishmaniasis: increased ex vivo levels and correlation with clinical data. J Leukoc Biol 79: 36-39. (Pubitemid 43054247)
33. Naume B, Shalaby R, Lesslauer W, Espevik T, 1991. Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. J Immunol 146: 3045-3048.